Suchergebnisse - "Hess, Georg"

PubPharm (26)

1

Mosunetuzumab Safety Profile in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma : Clinical Management Experience From a Pivotal Phase I/II Trial

enthalten in: Clinical lymphoma, myeloma & leukemia | 2024

von Matasar, M. | Bartlett, N. | Shadman, M. | +13

2

First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia

enthalten in: The New England journal of medicine | 2023

von Eichhorst, B. | Niemann, C. | Kater, A. | +148

CommentIn: Nat Rev Clin Oncol. 2023 Aug;20(8):503. - PMID 37237098

3

Safety of AFM11 in the treatment of patients with B-cell malignancies : findings from two phase 1 studies

enthalten in: Trials | 2023

von Topp, M. | Dlugosz-Danecka, M. | Skotnicki, A. | +13

4

Identification of a genetic signature enriching for response to ibrutinib in relapsed/refractory follicular lymphoma in the DAWN phase 2 trial

enthalten in: Cancer medicine | 2022

von Balasubramanian, S. | Hodkinson, B. | Schuster, S. | +10

5

Comparison of two doses of intravenous temsirolimus in patients with relapsed/refractory mantle cell lymphoma

enthalten in: Leukemia & lymphoma | 2018

von Jurczak, W. | Ramanathan, S. | Giri, P. | +8

6

Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib : a pooled analysis from three open-label studies

enthalten in: British journal of haematology | 2017

von Rule, S. | Dreyling, M. | Goy, A. | +12

7

Checkpoint Inhibition in Non-Hodgkin's Lymphoma

enthalten in: Oncology research and treatment | 2017

von Heß, G.

8

Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma : Final Results From a Phase I Study

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2016

von Goebeler, M. | Knop, S. | Viardot, A. | +21

9

Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma

enthalten in: Blood | 2016

von Viardot, A. | Goebeler, M. | Hess, G. | +10

10

Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma : an international, randomised, open-label, phase 3 study

enthalten in: Lancet (London, England) | 2016

von Dreyling, M. | Jurczak, W. | Jerkeman, M. | +20

ErratumIn: Lancet. 2016 Feb 20;387(10020):750